Breaking News, Collaborations & Alliances

Oragenics and KBI Biopharma Enter Covid-19 Vaccine Development Partnership

KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Oragenics has entered into an agreement with KBI Biopharma for the process transfer, process optimization and cGMP manufacturing of the company’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line. The agreement covers, among other things, both a 200L demonstration run and a 500L cGMP run. “We are delighted to enter into a development collaboration for our SARS-CoV-2 intranasal vaccine candidate with an outstanding commercial partner,” said Frederick Tel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters